THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q’25
Strong financial position with cash and cash equivalents totaling $255.3 million as of June 30, 2024
Read more at globenewswire.comThird Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
THIRD HARMONIC BIO INC
NASDAQ:THRD (2/11/2025, 8:00:01 PM)
After market: 3.26 +0.01 (+0.31%)3.25
-1.4 (-30.11%)
THRD Latest News and Analysis
11 hours ago - ChartmillTuesday's session: top gainers and losersIntrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
16 hours ago - ChartmillTuesday's session: gap up and gap down stocksLet's have a look at the gap up and gap down stocks in today's session.
18 hours ago - ChartmillWhich stocks are moving before the opening bell on Tuesday?As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
